Cowan, Liebowitz & Latman, P.C. company information, Employees & Contact Information

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study Journal of Hematology & Oncology

Immunoglobulin Replacement Not Associated With Fewer Infections in CLL Cure Today

Pirtobrutinib Monotherapy Meets Primary PFS End Point in Treatment-Naive CLL/SLL OncLive

Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL Applied Clinical Trials

Genetics or Microenvironment: What Drives CLL Progression? Medscape

Exercise could ease symptoms for people with chronic lymphocytic leukaemia (CLL) – new study The Conversation

Common Energy Drink Additive Could Be Fueling Growth in Leukemia ScienceAlert

Subcutaneous Epcoritamab Elicits Deep Responses in Heavily Pretreated CLL CancerNetwork

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL OncLive

Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL The ASCO Post

Survival Rates and Life Expectency for Chronic Lymphocytic Leukemia (CLL) Healthline

Acute Myeloid Leukemia (AML): Practice Essentials, Pathophysiology, Etiology Medscape eMedicine

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice Nature

Pirtobrutinib Demonstrates ORR Noninferiority vs Ibrutinib in BTK Inhibitor–Naive CLL/SLL OncLive

Acalabrutinib Combo Promising as Frontline Treatment for CLL Medscape

Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions OncLive

Acute Lymphoblastic Leukemia (ALL): Practice Essentials, Pathophysiology, Etiology Medscape eMedicine

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL OncLive

Venetoclax-Obinutuzumab: CLL’s New Power Duo? Medscape

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL OncLive

Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL AJMC

Chronic lymphocytic leukemia treatment algorithm 2022 Nature

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL OncLive

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia OncLive

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs | Leukemia Nature

Jaypirca Shows Improvements Over Imbruvica in CLL/SLL Cure Today

Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL OncLive

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL Pharmacy Times

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL OncLive

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL OncLive

Indirect Comparison Shows Zanubrutinib Outperforms Acalabrutinib/Venetoclax in Frontline CLL OncLive

Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL OncLive

Patients With Progressive CLL After Zanubrutinib or Ibrutinib Therapy Often Do Not Have BTK-Mutated Disease OncLive

Orelabrutinib Wins Approval in China for First-Line CLL and SLL OncLive

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL OncLive

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features Nature

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Bristol Myers Squibb

Machine learning can identify newly diagnosed patients with CLL at high risk of infection Nature

Multiple omics levels of chronic lymphocytic leukemia - Cell Death Discovery Nature

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019 | Blood Cancer Journal Nature

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Nature

Advancing Treatment Selection in CLL Management Pharmacy Times

Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia? Targeted Oncology

FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL OncLive

Ibrutinib for CLL: Mechanism of action and clinical considerations Lymphoma Hub

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL OncLive

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study Nature

Pirtobrutinib in Pretreated Patients With CLL/SLL: Applying Lessons From Clinical Trials to Clinical Practice Journal of Hematology Oncology Pharmacy

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus Nature

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia Nature

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY - eClinicalMedicine The Lancet

Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial OncLive

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets Nature

Venetoclax Combos Improve Progression-Free Survival in CLL Medscape

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL OncLive

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies Nature

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication Nature

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia Nature

Covalent BTK Inhibitors: A Review of the Evidence in Chronic Lymphocytic Leukemia Pharmacy Times

FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL Medscape

Does Exposure to Agent Orange Increase Risk for CLL? Healthline

Chronic Lymphocytic Leukemia OncLive

Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns Nature

Post-Mohs Bleeding Risk in Patients on Ibrutinib for CLL Studied Medscape

Diet and CLL: Foods to Eat, Avoid, and the Connection Healthline

Calquence approved in the US for adult patients with chronic lymphocytic leukaemia AstraZeneca

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL Nature

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data The Lancet

Treatment of Elderly Patients With CLL Medscape

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL The ASCO Post